Across TCGA pan-cancer cohorts, MXD3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MXD3 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MXD3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MXD3 expression acts as an unfavorable survival marker.

HNSC and PRAD are the cancer types where MXD3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.138	0.751	<.001	48	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: MXD3 tumor-vs-normal RNA expression · all MXD3 data types